secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001193125-26-041169
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology CEO Dr. Lara Sullivan steps down; board member Tom Civik appointed interim CEO
--------------------------------------------------------------------------------

- Effective February 2, 2026, Dr. Lara Sullivan stepped down as President, CEO, and CMO of Pyxis Oncology.
- Board appointed Thomas Civik, a current director, as Interim CEO; base salary $710K, target bonus 60%.
- Civik receives initial option grant (1.1% of shares) vesting monthly over 12 months, plus top-up (0.4%) upon successful transaction.
- Board launched search for permanent CEO; Civik previously led Five Prime through its $1.9B acquisition by Amgen.
- Lead program MICVO continues Phase 1/2 trials for head and neck squamous cell carcinoma; clinical operations unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526041169/0001193125-26-041169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526041169/pyxs-20260206.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-041169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer